Inactive Instrument

COSMO Pharmaceuticals SA Share Price Swiss Exchange

Equities

LU1202320294

Pharmaceuticals

End-of-day quote Swiss Exchange
- CHF - Intraday chart for COSMO Pharmaceuticals SA

Financials

Sales 2024 * 264M 284M 255M 22.39B Sales 2025 * 242M 260M 234M 20.55B Capitalization 1.17B 1.26B 1.13B 99.28B
Net income 2024 * 124M 133M 120M 10.53B Net income 2025 * 76M 81.8M 73.62M 6.46B EV / Sales 2024 * 3.98 x
Net cash position 2024 * 120M 129M 116M 10.15B Net cash position 2025 * 210M 226M 204M 17.87B EV / Sales 2025 * 3.96 x
P/E ratio 2024 *
9.5 x
P/E ratio 2025 *
12.8 x
Employees -
Yield 2024 *
2.88%
Yield 2025 *
1.06%
Free-Float 44.36%
More Fundamentals * Assessed data

Latest transcript on COSMO Pharmaceuticals SA

Managers TitleAgeSince
Director of Finance/CFO 52 31/05/16
Chairman 61 31/12/05
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Founder 69 31/12/96
Director/Board Member 69 31/03/12
Chairman 61 31/12/05
More insiders
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
More about the company